scholarly journals False‐positive urine screen test for MDMA in a patient exposed to mebeverine

Author(s):  
Francesca Bedussi ◽  
Elisabetta Acerbis ◽  
Roberta Noseda ◽  
Davide Demagistri ◽  
Emanuela Zamprogno ◽  
...  
2021 ◽  
Vol 2021 ◽  
pp. 1-3
Author(s):  
Sumit Sohal ◽  
Mina Sous ◽  
Gauri Pethe ◽  
Shanmugha V. Padmanabhan ◽  
Rajesh Akbari ◽  
...  

Advanced heart failure patients commonly suffer from ventricular arrhythmias which can be managed by antiarrhythmic drugs like mexiletine. These ventricular arrhythmias can be complicated by illicit drug use which alter outcomes and can potentially impact the patient-physician relationship through countertransference. However, mexiletine can lead to false positive urine drug screen testing for amphetamine, and these false-positive urine drug screen test results can affect the decision-making process. Health care providers should be aware of this fact and should either use confirmatory testing or look for confounding compounds in patients who deny using illicit substances and have a positive urine drug screen. Our patient is 64 years old who arrived at the emergency department after experiencing a shock by his intracardiac defibrillator. The patient tested positive for amphetamine on his urine drug screen and was later ruled out by confirmatory quantitative testing.


2021 ◽  
Author(s):  
Keisuke Yoshida ◽  
Masahiko Yazawa ◽  
Maho Terashita ◽  
Yugo Shibagaki ◽  
Naoto Tominaga

1999 ◽  
Vol 45 (12) ◽  
pp. 2109-2119 ◽  
Author(s):  
Laurence A Cole ◽  
Shohreh Shahabi ◽  
Utku A Oz ◽  
Ray O Bahado-Singh ◽  
Maurice J Mahoney

Abstract Background: Serum human chorionic gonadotropin (hCG) and hCG free β-subunit tests are used in combination with unconjugated estriol and α-fetoprotein in the triple screen test, and with the addition of inhibin-A in the quadruple marker test for detecting Down syndrome in the second trimester of pregnancy. These tests have a limited detection rate for Down syndrome: ∼40% for hCG or free β-subunit alone, ∼60% for the triple screen test, and ∼70% for the quadruple marker test, all at 5%, or a relatively high, false-positive rate. New tests are needed with higher detection and lower false rates. Hyperglycosylated hCG (also known as invasive trophoblast antigen or ITA) is a new test. It specifically detects a unique oligosaccharide variant of hCG associated with Down syndrome pregnancies. We evaluated this new Down syndrome-directed test in prenatal diagnosis. Methods: Hyperglycosylated hCG was measured in urine samples from women undergoing amniocentesis for advanced maternal age concerns at 14–22 weeks of gestation, 1448 with normal karyotype and 39 with Down syndrome fetuses. Results: The median hyperglycosylated hCG value was 9.5-fold higher in Down syndrome cases (9.5 multiples of the normal karyotype median). The single test detected 80% of Down syndrome cases at a 5% false-positive rate. Urine hyperglycosylated hCG was combined with urine β-core fragment (urine breakdown product of serum hCG free β-subunit), serum α-fetoprotein, and maternal age-related risk. This urine-serum combination detected 96% of Down syndrome cases at a 5% false-positive rate, 94% of cases at a 3% false-positive rate, and 71% of cases at a 1% false-positive rate. These detection rates exceed those of any previously reported combination of biochemical markers. Conclusions: Hyperglycosylated hCG is a new base marker for Down syndrome screening in the second trimester of pregnancy. The measurement of hyperglycosylated hCG can fundamentally improve the performance of Down syndrome screening protocols.


2014 ◽  
Vol 15 (5) ◽  
pp. 2251-2255 ◽  
Author(s):  
Kazumasa Matsumoto ◽  
Masaomi Ikeda ◽  
Takahiro Hirayama ◽  
Morihiro Nishi ◽  
Tetsuo Fujita ◽  
...  

2003 ◽  
Vol 43 (2) ◽  
pp. 146-151 ◽  
Author(s):  
Martin G Friedrich ◽  
Angelika Hellstern ◽  
Marieta I Toma ◽  
Peter Hammerer ◽  
Hartwig Huland

2002 ◽  
Vol 18 (5) ◽  
pp. 401 ◽  
Author(s):  
Shannon Manzi ◽  
Terence Law ◽  
Michael W. Shannon

1985 ◽  
Vol 31 (7) ◽  
pp. 1250-1251 ◽  
Author(s):  
F S Apple ◽  
M K Googins ◽  
S Kastner ◽  
K Nevala ◽  
S Edmondson ◽  
...  
Keyword(s):  

Author(s):  
H Madhavaram ◽  
T Patel ◽  
C Kyle

Abstract We encountered unexpected false-positive urine results in three patients for amphetamine-type substances by immunoassay (IA), measured as part of community drug prevention programs. Kavain was identified in all three urine samples by gas chromatography-mass spectrometry (GC-MS). No other potential cross-reactants were found. Kavain is a kava-lactone present in kava, a ceremonial and recreational drink derived from the roots and stems of the plant Piper methysticum. It is consumed regularly by many indigenous Pacific and Australian Aboriginal communities. Urine IA was performed on a Beckman Coulter AU480 Analyzer using cloned enzyme donor immunoassay (CEDIA) amphetamine-type substance reagent and DRI ethanol reagent. We purchased three different kava powders from local kava clubs and dissolved in ethanol, then evaporated and reconstituted in blank urine and analyzed by IA, GC-MS for amphetamine-type substances. Additionally, authentic kavain standard was also tested for cross-reactivity by IA and analyzed by GC-MS to compare the mass fragmentation pattern and retention time with the kava powder and patient specimens. The patient urine samples tested positive by CEDIA IA for amphetamines. However, when analyzed by GC-MS, they were negative for amphetamine-type but contained kavain. The kava powders and kavain standard all cross-reacted with the amphetamine IA to give falsely detected results. GC-MS did not identify any amphetamine-type compounds in any of the kava powders nor in the kavain standard. To our knowledge, this is the first report of false-positive amphetamine measurements due to kavain, a component of the kava drink, widely consumed in Oceania and Australasia.


2012 ◽  
Vol 413 (1-2) ◽  
pp. 361-363 ◽  
Author(s):  
Mark A. Marzinke ◽  
Pamela Jarrar ◽  
Meredith Atkinson ◽  
Richard L. Humphrey ◽  
Barbara Detrick ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document